May 25, 2018 12:09 AM ET

Company Overview of Sanaria, Inc.

Company Overview

9800 Medical Center Drive

Suite A209

Rockville, MD 20850

United States

Key Executives for Sanaria, Inc.

Sanaria, Inc. does not have any Key Executives recorded.

Sanaria, Inc. Key Developments

Sanaria, Inc. Presents at VACCINES R&D-2017, Nov-13-2017 11:30 AM

Sanaria, Inc. Presents at VACCINES R&D-2017, Nov-13-2017 11:30 AM. Venue: Sheraton Reston Hotel, 11810 Sunrise Valley Dr, Reston, Virginia, United States. Speakers: Stephen L. Hoffman.

Sanaria, Inc. Announces Publication of Encouraging Results from Malaria Study

Sanaria Inc. has announced the publication of encouraging results from a study evaluating the safety and efficacy of PfSPZ Vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed Malian adult in The Lancet Infectious Diseases journal. Investigators reported that Sanaria PfSPZ Vaccine protected against natural infections of Plasmodium falciparum, the leading cause of malaria deaths and that protection was sustained for the 24 weeks of the study in an area of intense malaria transmission. The study was conducted in Doneguebougou, Mali and was led by Dr. Mahamadou Sissoko of the Malaria Research and Training Center at the University of Science, Techniques and Technologies of Bamako, Mali and by Dr. Sara Healy of the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland. In the Mali study, five doses of PfSPZ Vaccine were administered to 44 subjects and saltwater placebo was given to 44 subjects. Volunteers were followed for six months through the subsequent rainy season to determine the presence of malaria parasites in the blood. While a staggering 93% of the placebo group had one or more infections, only 66% of the vaccinated subjects acquired an infection and in those vaccinated subjects who became infected, the time to infection was delayed. This represents 48% protective efficacy by time-to-event analysis and 29% efficacy by proportional analysis. There were no differences in adverse events between the vaccinated group and the placebo group.

Similar Private Companies By Industry

Company Name Region
Aryzta Us Holdings I Corp. United States
Michael Anthony Hernandez, A Professional Corp United States
2018 Permian Basin JV United States
Achievement Holdings LLC United States
Advanced Energy Machines United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sanaria, Inc., please visit www.sanaria.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.